This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck & Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

Hypercholesterolemia, a type of hyperlipidemia, is a disorder in which there are elevated LDL cholesterol levels in the blood. It affects approximately 86 million adults in the U.S. and is a major risk driver for ASCVD, accounting for 85% of cardiovascular deaths.

Enlicitide is an investigational, potentially first oral PCSK9 inhibitor designed to lower LDL-C via the same biological mechanism as currently approved monoclonal antibody, injectable PCSK9 inhibitors but in a daily pill form.

Also Read: Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck’s Keytruda ...